insulin-like growth factor i

Insulin-like Growth Factor II (IGF-2), the primary somatomedin in human serum, exerts both permissive and direct influences on neurite outgrowth and significantly improves the survival of sympathetic and sensory neurons [1] [2].

IGF-I (30-41) is a fragment of Insulin-like Growth Factor I (IGF-I) comprising amino acids 30 to 41.

IGF-I (24-41) is a 24-41 amino acid fragment of Insulin-like Growth Factor I (IGF-I), which contributes to systemic GH activities and exhibits various properties such as anabolic, antioxidant, anti-inflammatory, and cytoprotective.

Suramin Sodium Salt (BAY-205) is a sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.

NBI-31772 hydrate is a powerful inhibitor of the interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). It acts as a nonpeptide ligand, effectively releasing bioactive IGF-I from the IGF-I/IGFBP-3 complex (Ki values for all six human subtypes range from 1-24 nM). This compound demonstrates significant anxiolytic and antidepressant-like effects [1] [2] [3].

H-1356 is an insulin-like growth factor 1(IGF-I) analog that inhibits autophosphorylation of IGF-I receptor.

Mecasermin (Human IGF-I; FK 780), a recombinant form of human insulin-like growth factor I (IGF-I), is promising for investigating growth failure attributed to growth hormone (GH) insensitivity due to defects in GH receptors or the presence of GH-inhibiting antibodies [1].

IGF-I (30-41) (TFA) is a fragment of Insulin-like Growth Factor I (IGF-I), comprising amino acids 30 to 41, that plays a role in systemic GH (Growth Hormone) activities and exhibits anabolic, antioxidant, anti-inflammatory, and cytoprotective properties [1].

Insulin-like Growth Factor I (24-41) TFA, a fragment comprising amino acids 24 to 41 of the full IGF-I TFA molecule, is a variant of IGF-I TFA, which itself is a 70 amino acid polypeptide hormone. This hormone serves as a trophic factor beneficial for both neurons and glial cells, playing a significant role in mediating the effects of growth hormone (GH) on systemic growth. Additionally, IGF-I TFA exhibits anabolic, antioxidant, anti-inflammatory, and cytoprotective properties. The specific fragment IGF-I (24-41) TFA is involved in regulating somatic growth as well as behavioral development [1] [2] [3].

S961 acetate is a selective and high-affinity antagonist of the insulin receptor (IR), demonstrating IC50 values of 0.048 nM for HIR-A, 0.027 nM for HIR-B, and 630 nM for the human insulin-like growth factor I receptor (HIGF-IR) in SPA assays [1].

Anti-IGF1R/CD221 Antibody is a highly specific monoclonal antibody targeting the Type I Insulin-like Growth Factor Receptor (IGF-1R/CD221). By binding to the extracellular domain of IGF-1R, this antibody effectively blocks the interaction with its ligands IGF-1 and IGF-2, thereby inhibiting the activation of downstream PI3K/Akt and MAPK signaling pathways. It is a vital tool for researching tumor cell growth inhibition, apoptosis induction, and transmembrane signaling mechanisms.

IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

IGF-I 30-41 acetate(82177-09-1 free base) (Insulin-like Growth Factor I (30-41) acetate) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I).

IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).IGF-I (24-41) (TFA) is amino acids 24 to 41 fragment of Insulin-like Growth

S961 TFA is A high affinity insulin receptor (IR) antagonist with IC50 for hir-a, hir-b and human insulin-like growth factor I receptor (higf-ir) at 0.048, 0.027 and 630 nM, respectively.

S961 is a high-affinity, selective insulin receptor (IR) antagonist with IC50 values of 0.048 nM for HIR-A, 0.027 nM for HIR-B, and 630 nM for human insulin-like growth factor I receptor (HIGF-IR) in scintillation proximity assays.